8/6/2009

Osiris Therapeutics established a biosurgery unit that focuses on developing and commercializing biotech devices for orthopedic procedures. The division comprises doctors, scientists, and regulatory and manufacturing experts who developed Osteocel, a line of medical devices sold by Osiris to NuVasive for $85 million.

Related Summaries